InIn BRCA and LIHC, SUV39H2 overexpression was further associated with clinical features such as younger patient age, advanced T stage, and molecular subtypes, suggesting that SUV39H2 may contribute to more aggressive tumor phenotypes (40). Here, SUV39H2 is linked to neoplasm.